A method for assessing rheumatoid arthritis disease activity, said method comprising: obtaining a first dataset associated with a first sample from a first subject comprising quantitative data for each of the following markers: chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1); C-reactive protein, pentraxin-related (CRP); epidermal growth factor (beta-urogastrone) (EGF); interleukin 6 (interferon, beta 2) (IL6); leptin (LEP); matrix metallopeptidase 1 (interstitial collagenase) (MMP1); matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3); resistin (RETN); serum amyloid A1 (SAA1); tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A); vascular cell adhesion molecule 1 (VCAM1); and, vascular endothelial growth factor A (VEGFA); wherein said first sample comprises a plurality of analytes; wherein said first dataset is obtained by contacting said first sample with a reagent; generating a plurality of complexes between said reagent and said plurality of analytes; detecting said plurality of complexes to obtain said first dataset associated with said first sample, wherein said first dataset comprises quantitative data for said markers; and determining a first disease activity score from said first dataset using an interpretation function, wherein said interpretation function is a predictive model derived using an algorithm, wherein said algorithm combines the quantitative data for said markers, and wherein said interpretation function provides a quantitative measure of rheumatoid arthritis (RA) disease activity in said first subject that is predictive of a clinical assessment of RA disease activity. obtaining a first dataset associated with a first sample from a first subject comprising quantitative data for each of the following markers: chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1); C-reactive protein, pentraxin-related (CRP); epidermal growth factor (beta-urogastrone) (EGF); interleukin 6 (interferon, beta 2) (IL6); leptin (LEP); matrix metallopeptidase 1 (interstitial collagenase) (MMP1); matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3); resistin (RETN); serum amyloid A1 (SAA1); tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A); vascular cell adhesion molecule 1 (VCAM1); and, vascular endothelial growth factor A (VEGFA); wherein said first sample comprises a plurality of analytes; wherein said first dataset is obtained by contacting said first sample with a reagent; generating a plurality of complexes between said reagent and said plurality of analytes; detecting said plurality of complexes to obtain said first dataset associated with said first sample, wherein said first dataset comprises quantitative data for said markers; and determining a first disease activity score from said first dataset using an interpretation function, wherein said interpretation function is a predictive model derived using an algorithm, wherein said algorithm combines the quantitative data for said markers, and wherein said interpretation function provides a quantitative measure of rheumatoid arthritis (RA) disease activity in said first subject that is predictive of a clinical assessment of RA disease activity. <EOS>